Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin - a UK Perspective
| Autor: | Richard Hellmund, Deirdre Blissett, Raimund Weitgasser |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
genetic structures endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism 03 medical and health sciences Flash (photography) 0302 clinical medicine Endocrinology Diabetes mellitus cost medicine In patient 030212 general & internal medicine health care economics and organizations calculation Endocrine and Autonomic Systems business.industry Insulin Diabetes Type 2 Diabetes Mellitus nutritional and metabolic diseases Monitoring system medicine.disease monitoring Emergency medicine Resource use flash Cost calculation business hypoglycaemia |
| Zdroj: | European Endocrinology |
| ISSN: | 1758-3780 |
| Popis: | Aims:Estimate the costs associated with flash glucose monitoring as a replacement for routine self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus (T2DM) using intensive insulin, from a UK National Health Service (NHS) perspective.Methods:The base-case cost calculation used the frequency of SMBG and healthcare resource use observed in the REPLACE trial. Scenario analyses considered SMBG at the flash monitoring frequencies observed in the REPLACE trial (8.3 tests per day) and a real-world analysis (16 tests per day).Results:Compared with 3 SMBG tests per day, flash monitoring would cost an additional £585 per patient per year, offset by a £776 reduction in healthcare resource use, based on reductions in emergency room visits (41%), ambulance call-outs (66%) and hospital admissions (77%) observed in the REPLACE trial. Per patient, the estimated total annual cost for flash monitoring was £191 (13.4%) lower than for SMBG. In the scenarios based on acquisition cost alone, flash monitoring was cost-neutral versus 8.3 SMBG tests per day (5% decrease) and cost-saving at higher testing frequencies.Conclusion:From a UK NHS perspective, for patients with T2DM using intensive insulin, flash monitoring is potentially cost-saving compared with routine SMBG irrespective of testing frequency. Keywords |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|